Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

Research Grants 3 show all

Patents 2,799show all

  • 878
    A61K - Preparations for medical, dental, or toilet purposes
  • 691
    C07D - Heterocyclic compounds
  • 273
    C07C - Acyclic or carbocyclic compounds
  • 205
    C07K - Peptides
  • 92
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 73
    C07B - General methods of organic chemistry
  • 67
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 41
    C12N - Microorganisms or enzymes
  • 41
    Y02A - Technologies for adaptation to climate change
  • 30
    C07H - Sugars

Clinical Trials 233show all

66N/A59Phase 256Phase 319Phase 114Phase 412Phase 1/Phase 24Other

SEC Filings show all


251
8-K

47
10-Q

10
10-K

Contact Information

41 Moores Road
Malvern, PA 19355
United States

Overview

Total FundingEmployeesLast Funding DateStatus
1001-5000Acquired